151 related articles for article (PubMed ID: 19197325)
1. Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker.
Fisher MB; Zhang XQ; McConkey DJ; Benedict WF
Cancer Gene Ther; 2009 Jul; 16(7):567-72. PubMed ID: 19197325
[TBL] [Abstract][Full Text] [Related]
2. Direct gene transfer of adenoviral-mediated interferon α into human bladder cancer cells but not the bystander factors produced induces endoplasmic reticulum stress-related cytotoxicity.
Zhang XQ; Yang Z; Benedict WF
Cancer Gene Ther; 2011 Apr; 18(4):260-4. PubMed ID: 21183949
[TBL] [Abstract][Full Text] [Related]
3. Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study.
Benedict WF; Fisher M; Zhang XQ; Yang Z; Munsell MF; Dinney CN
Cancer Gene Ther; 2014 Mar; 21(3):91-4. PubMed ID: 24503570
[TBL] [Abstract][Full Text] [Related]
4. Autophagy is induced by adenoviral-mediated interferon alpha treatment in interferon resistant bladder cancer and normal urothelial cells as a cell death protective mechanism but not by the bystander factors produced.
Zhang XQ; Dunner K; Benedict WF
Cancer Gene Ther; 2010 Aug; 17(8):579-84. PubMed ID: 20489789
[TBL] [Abstract][Full Text] [Related]
5. Conditioned medium from Ad-IFN-alpha-infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect.
Zhang X; Dong L; Chapman E; Benedict WF
Cancer Gene Ther; 2008 Dec; 15(12):817-22. PubMed ID: 18617914
[TBL] [Abstract][Full Text] [Related]
6. Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects.
Zhang X; Yang Z; Dong L; Papageorgiou A; McConkey DJ; Benedict WF
Cancer Gene Ther; 2007 Mar; 14(3):241-50. PubMed ID: 17096027
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.
de Haas EC; di Pietro A; Simpson KL; Meijer C; Suurmeijer AJ; Lancashire LJ; Cummings J; de Jong S; de Vries EG; Dive C; Gietema JA
Neoplasia; 2008 Oct; 10(10):1041-8. PubMed ID: 18813353
[TBL] [Abstract][Full Text] [Related]
8. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein.
Benedict WF; Tao Z; Kim CS; Zhang X; Zhou JH; Adam L; McConkey DJ; Papageorgiou A; Munsell M; Philopena J; Engler H; Demers W; Maneval DC; Dinney CP; Connor RJ
Mol Ther; 2004 Sep; 10(3):525-32. PubMed ID: 15336652
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.
Cummings J; Hodgkinson C; Odedra R; Sini P; Heaton SP; Mundt KE; Ward TH; Wilkinson RW; Growcott J; Hughes A; Dive C
Mol Cancer Ther; 2008 Mar; 7(3):455-63. PubMed ID: 18347133
[TBL] [Abstract][Full Text] [Related]
10. Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
Linder S; Olofsson MH; Herrmann R; Ulukaya E
Expert Rev Mol Diagn; 2010 Apr; 10(3):353-9. PubMed ID: 20370591
[TBL] [Abstract][Full Text] [Related]
11. Cytokeratin 18 cell death assays as biomarkers for quantification of apoptosis and necrosis in COVID-19: a prospective, observational study.
Henry BM; Cheruiyot I; Benoit SW; Sanchis-Gomar F; Lippi G; Benoit J
J Clin Pathol; 2022 Jun; 75(6):410-415. PubMed ID: 33789919
[TBL] [Abstract][Full Text] [Related]
12. Propofol or sevoflurane anaesthesia does not affect hepatic integrity as assessed by the M30 & M65 cell death markers & liver enzymes.
Chondrogiannis K; Hadziyannis E; Fassoulaki A
Indian J Med Res; 2014 Nov; 140(5):630-6. PubMed ID: 25579144
[TBL] [Abstract][Full Text] [Related]
13. Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
Cummings J; Ranson M; Lacasse E; Ganganagari JR; St-Jean M; Jayson G; Durkin J; Dive C
Br J Cancer; 2006 Jul; 95(1):42-8. PubMed ID: 16804528
[TBL] [Abstract][Full Text] [Related]
14. Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer.
Micha D; Cummings J; Shoemaker A; Elmore S; Foster K; Greaves M; Ward T; Rosenberg S; Dive C; Simpson K
Clin Cancer Res; 2008 Nov; 14(22):7304-10. PubMed ID: 19010845
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
Ozturk B; Coskun U; Sancak B; Yaman E; Buyukberber S; Benekli M
Int Immunopharmacol; 2009 May; 9(5):645-8. PubMed ID: 19249390
[TBL] [Abstract][Full Text] [Related]
16. Serum cytokeratin 18 as a biomarker for gastric cancer.
Oyama K; Fushida S; Kinoshita J; Okamoto K; Makino I; Nakamura K; Hayashi H; Inokuchi M; Nakagawara H; Tajima H; Fujita H; Takamura H; Ninomiya I; Kitagawa H; Fujimura T; Ohta T
Clin Exp Med; 2013 Nov; 13(4):289-95. PubMed ID: 22825587
[TBL] [Abstract][Full Text] [Related]
17. Direct cytotoxicity produced by adenoviral-mediated interferon α gene transfer in interferon-resistant cancer cells involves ER stress and caspase 4 activation.
Yang Z; Zhang XQ; Dinney CN; Benedict WF
Cancer Gene Ther; 2011 Sep; 18(9):609-16. PubMed ID: 21681220
[TBL] [Abstract][Full Text] [Related]
18. Construction of recombinant human IFNα-2b BCG and its antitumor effects on bladder cancer cells in vitro.
Sun E; Nian X; Liu C; Fan X; Han R
Genet Mol Res; 2015 Apr; 14(2):3436-49. PubMed ID: 25966110
[TBL] [Abstract][Full Text] [Related]
19. Cytokeratin markers come of age.
Linder S
Tumour Biol; 2007; 28(4):189-95. PubMed ID: 17717426
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer.
Adam L; Black PC; Kassouf W; Eve B; McConkey D; Munsell MF; Benedict WF; Dinney CP
J Urol; 2007 May; 177(5):1900-6. PubMed ID: 17437845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
